Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients

May 28, 2016 updated by: Li Zhang, Sun Yat-sen University

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients.

Evaluate the efficacy and safety of Monosialoganglioside(GM1) to prevent the neurotoxicity induced by cisplatin

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

NSCLC patients received a cisplatin-based doublet chemotherapy are included in this trial. Patients are randomly assigned into the experimental group and control group based on segmented block randomized method. After enrollment, patients should complete four or six chemotherapy and GM1/placebo injection. During the 3w per cycle chemotherapy, cisplatin injection is conducted in D1/D1-3, GM1/placebo (80mg+250ml N.S) is injected from D0 to D3. Neurotoxicity evaluation and quality of life (FACT-NTX and EROTC scale) assessment will be conducted every cycle and 3w/11w/19w after the chemotherapy.

Study Type

Interventional

Enrollment (Anticipated)

300

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • GuangZhou, Guangdong, China, 510030
        • Recruiting
        • Sun Yat-sen University Cancer Center
        • Contact:
        • Sub-Investigator:
          • Yan Huang, Doctor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Cytological and histological confirmation of non-small cell lung cancer (NSCLC) diagnosis, single sputum cytology diagnosis is not accepted
  • Expected survival period is more than 3 months
  • Enough blood function reservation: absolute neutrophil count (ANC) 2 x 10E9/L or higher;platelet count 100 x 109 /L or higher;hemoglobin 9 g/dL or higher.
  • Enough liver function reservation:the total bilirubin less than upper limit of normal;AST and ALT acuities were less than 2.5 times the upper limit of normal (ULN);Alkaline phosphatase 5 times the upper limit of normal (ULN) or less.
  • Clinical doctors identify patients suitable for standard doses of ganglioside drug therapy, and expected time of medication is at least six weeks
  • Within 4 weeks before treatment, did not receive other adverse reaction of drugs may cause similar neurotoxicity; 18 weeks before, did not received platinum-based drugs chemical treatment.
  • No more than 1 degree of the peripheral nervous system diseases exists before enrollment, also no other symptom or disease could affect the adverse reactions of neurotoxicity pathological.
  • Can't accept other adverse reactions may prevent neurotoxicity treatment or care after enrollment.
  • Sign the informed consent form.

Exclusion Criteria:

  • Patients with poor general condition, PS score more than 2 points
  • Women in pregnancy or lactation
  • Patients (male or female) have fertility possibility but not willing to or not to adopt effective contraception
  • With other neurological dysfunction which can cause inaccurate record of the occurrence of neurotoxicity and severity
  • Known or assignment of any of these products to test drugs allergic agent composition
  • Doctors think inappropriate for patients with ganglioside medication or estimated time of less than 6 weeks
  • Active infection (determined by the researcher)
  • According to the researcher's judgment, there is serious disease to endanger the safety of patients, or may prevent the patients from completing the study
  • Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Monosialoganglioside(GM1)
Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
Drug: Monosialoganglioside(GM1)
80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
Other Names:
  • Monosialotetrahexosylganglioside Sodium Injection
Placebo Comparator: normal saline
placebo 80mg + N.S 250ml,qd,D0-D3
Drug: normal saline
80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
incidence rate of neurotoxicity adverse events
Time Frame: up to 19 weeks after cisplatin chemotherapy
up to 19 weeks after cisplatin chemotherapy

Secondary Outcome Measures

Outcome Measure
Time Frame
neurotoxicity adverse events alleviation time
Time Frame: up to 19 weeks after the cisplatin based chemotherapy
up to 19 weeks after the cisplatin based chemotherapy

Other Outcome Measures

Outcome Measure
Time Frame
the quality of life of patients
Time Frame: up to 19 weeks after the cisplatin based chemotherapy
up to 19 weeks after the cisplatin based chemotherapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sun Yat-sen University

Collaborators

Southern Medical University, China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Anticipated)

August 1, 2016

Study Completion (Anticipated)

August 1, 2016

Study Registration Dates

First Submitted

June 17, 2013

First Submitted That Met QC Criteria

June 19, 2013

First Posted (Estimate)

June 20, 2013

Study Record Updates

Last Update Posted (Estimate)

June 1, 2016

Last Update Submitted That Met QC Criteria

May 28, 2016

Last Verified

May 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GM1-0324

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe